計算
純利益率 | = | 100 | × | IQVIAホールディングス株式会社に帰属する当期純利益1 | ÷ | 収益1 | |
---|---|---|---|---|---|---|---|
2022/12/31 | 7.57% | = | 100 | × | 1,091) | ÷ | 14,410) |
2021/12/31 | 6.96% | = | 100 | × | 966) | ÷ | 13,874) |
2020/12/31 | 2.46% | = | 100 | × | 279) | ÷ | 11,359) |
2019/12/31 | 1.72% | = | 100 | × | 191) | ÷ | 11,088) |
2018/12/31 | 2.49% | = | 100 | × | 259) | ÷ | 10,412) |
2017/12/31 | 13.44% | = | 100 | × | 1,309) | ÷ | 9,739) |
2016/12/31 | 1.67% | = | 100 | × | 115) | ÷ | 6,878) |
2015/12/31 | 6.75% | = | 100 | × | 387) | ÷ | 5,738) |
2014/12/31 | 6.53% | = | 100 | × | 356) | ÷ | 5,460) |
2013/12/31 | 4.44% | = | 100 | × | 227) | ÷ | 5,100) |
レポートに基づく: 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31).
1 百万米ドル
競合他社との比較
IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022/12/31 | 7.57% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.27% | 35.64% | 15.47% | 26.16% |
2021/12/31 | 6.96% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 27.04% | 50.25% | 19.70% | 26.20% |
2020/12/31 | 2.46% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.95% | 41.35% | 19.79% | 24.54% |
2019/12/31 | 1.72% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 23.96% |
2018/12/31 | 2.49% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 24.52% |
2017/12/31 | 13.44% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 16.28% |
2016/12/31 | 1.67% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | 16.80% |
2015/12/31 | 6.75% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | 7.11% |
2014/12/31 | 6.53% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | 12.18% |
2013/12/31 | 4.44% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | 11.05% |
レポートに基づく: 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
IQVIA Holdings Inc. | 製薬、バイオテクノロジー、ライフサイエンス | |
---|---|---|
2022/12/31 | 7.57% | 22.40% |
2021/12/31 | 6.96% | 23.35% |
2020/12/31 | 2.46% | 13.81% |
2019/12/31 | 1.72% | 23.18% |
2018/12/31 | 2.49% | 19.48% |
2017/12/31 | 13.44% | 13.13% |
2016/12/31 | 1.67% | 20.86% |
2015/12/31 | 6.75% | 21.21% |
2014/12/31 | 6.53% | 21.38% |
2013/12/31 | 4.44% | 22.06% |
レポートに基づく: 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31).
業界との比較: 医療
IQVIA Holdings Inc. | 医療 | |
---|---|---|
2022/12/31 | 7.57% | 10.25% |
2021/12/31 | 6.96% | 10.89% |
2020/12/31 | 2.46% | 7.78% |
2019/12/31 | 1.72% | 10.20% |
2018/12/31 | 2.49% | 9.25% |
2017/12/31 | 13.44% | 7.79% |
2016/12/31 | 1.67% | 9.94% |
2015/12/31 | 6.75% | 10.96% |
2014/12/31 | 6.53% | 11.39% |
2013/12/31 | 4.44% | 11.98% |
レポートに基づく: 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31).